Is Inhibrx Biosciences, Inc. (INBX) overvalued? · rev $1.3M
Inhibrx Biosciences, Inc. (INBX) is a biotechnology company listed on US.
This page asks whether Inhibrx Biosciences, Inc. (INBX) looks expensive on cached numbers — not a short thesis.
Latest reported INBX revenue for 2025-12-31 was $1.3M. Net income was -$140.1M. Revenue was up 550.0% from 2024-12-31 to 2025-12-31. INBX currently screens at market cap $1.28B.
INBX currently screens at market cap $1.28B. A high multiple can be growth prepaid or a bubble. The filing has to explain the gap.
If the next INBX 8-K cuts growth or raises capex, this “expensive” read gets worse. Until then the SEC page is the source.
Not investment advice. Use the INBX stock page for the full model, not this heading.
Not investment advice.